GC
ALLO icon

Gratus Capital’s Allogene Therapeutics ALLO Stock Holding History

Gratus Capital’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-238,159
Closed -$2.57M – 226
2022
Q3 		$2.57M Buy
238,159
+24,173
+11% +$328K 0.27% 74
2022
Q2 		$2.44M Buy
213,986
+11,546
+6% +$102K 0.27% 71
2022
Q1 		$1.84M Buy
202,440
+10,569
+6% +$110K 0.18% 89
2021
Q4 		$2.86M Buy
+191,871
New +$3.39M 0.27% 75

Other funds holding ALLO

TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Gratus Capital's ALLO Position: Q4 2022 in Review

Gratus Capital sold out of Allogene Therapeutics (ALLO) in Q4 2022, closing a stake of 238,159 shares — an estimated $2.57M sold.

Gratus Capital first reported a position in ALLO in Q4 2021 and held it in 4 quarters. The position peaked at $2.86M in Q4 2021. 168 funds tracked by Wall St. Rank hold ALLO as of Q4 2022.

  • Gratus Capital reported no remaining Allogene Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Gratus Capital sold 238,159 Allogene Therapeutics shares in Q4 2022, an estimated $2.57M.
  • Gratus Capital first reported a position in Allogene Therapeutics in Q4 2021 and held it in 4 quarters.
  • Gratus Capital's Allogene Therapeutics position peaked at $2.86M in Q4 2021.
  • 168 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q4 2022.

Based on Gratus Capital's 13F filing for Q4 2022, filed 27 Jan 2023.